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ABSTRACT
Objective: To investigate the impact of Opioid-Induced Constipation (OIC) in the literature through the identifi cation of the risk factors, 
symptoms and treatments. Methods: We carried out a review of scientifi c publications available in the Virtual Health Library (VHL), the 
Scientifi c Electronic Library Online (SciELO), the Latin-American and Caribbean Center on Health Sciences Information (LILACS) and the 
Medical Literature Analysis and Retrieval System Online (MEDLINE) databases. The search was carried out using the descriptors “analgesic 
opioids”, “constipation” and “pain” in English, Portuguese and Spanish, correlated or isolated. We searched for publications dating from 2011 
to 2016 that investigated patients receiving treatment for pain with continuous use of opioids and with constipation as a clinical outcome. 
Results: The results highlighted constipation as the main secondary effect of opioids, which are very important for the control of cancer pain, 
and identifi ed the risk factors for the disease. In addition, patients who were well served by health professionals presented better adherence 
to OIC treatment. Conclusion: The OIC control provides abdominal comfort, self-care and reduction in treatment costs. The importance of 
training health professionals and promoting prevention and periodic monitoring of patients should be highlighted. In addition, diet therapy 
and drug therapy should be provided early.
Descriptors: Analgesics, Opioid; Constipation; Pain; Neoplasms.
RESUMO 
Objetivo: Investigar na literatura o impacto da constipação intestinal induzida por opioides (CIO) por meio da identifi cação dos seus 
fatores de risco, sintomas e tratamentos. Métodos: Realizou-se, entre fevereiro e março de 2016, um levantamento de publicações 
científi cas nas bases de dados eletrônicas Biblioteca Virtual em Saúde (BVS), Scientifi c Electronic Library Online (SciELO), Literatura 
Latino-Americana e do Caribe em Ciências da Saúde (LILACS) e Medical Literature Analysis and Retrieval System Online (MEDLINE), 
pesquisadas por meio dos descritores “analgésicos opioides”, “constipação intestinal” e “dor”, apresentados nos idiomas inglês, português 
e espanhol, correlacionados ou isolados, no período de 2011 a 2016, que investigassem pacientes em tratamento da dor com uso contínuo de 
medicamentos opioides e com desfecho clínico de constipação intestinal. Resultados: Os estudos apontaram a constipação intestinal como 
principal efeito secundário ao uso de opioides, os quais são muito importantes para o controle da dor de origem oncológica, assim como 
identifi caram os fatores de risco para o surgimento da doença. Além disso, pacientes que foram bem assistidos por profi ssionais de saúde 
apresentaram melhor adesão ao tratamento da CIO. Conclusão: O controle da CIO proporciona conforto abdominal, autocuidado e redução 
nos custos do tratamento, ressaltando que deve haver capacitação dos profi ssionais de saúde, prevenção e acompanhamento periódico, além 
da precocidade dos tratamentos dietoterápico e medicamentoso.
Descritores: Analgésicos Opioides; Constipação Intestinal; Dor; Neoplasias. 
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RESUMEN
Objetivo: Investigar en la literatura el impacto del estreñimiento inducido por opioides (EIO) a través de la identificación de sus factores de 
riesgo, síntomas y tratamientos. Métodos: Se realizó entre febrero y marzo de 2016 una búsqueda de publicaciones científicas en las bases 
de datos electrónicas Biblioteca Virtual en Salud (BVS), Scientific Electronic Library Online (SciELO), Literatura Latino-Americana y del 
Caribe en Ciencias de la Salud (LILACS) y Medical Literature Analysis and Retrieval System Online (MEDLINE) investigadas a través 
de los descriptores “analgésicos opioides”, “estreñimiento” y “dolor” en los idiomas inglés, portugués y español de manera individual o 
asociadas en el período entre 2011 y 2016 sobre investigaciones con pacientes en tratamiento del dolor en uso continuo de medicamentos 
opioides y desenlace clínico de estreñimiento. Resultados: Los estudios señalan el estreñimiento como principal efecto secundario del uso 
de opioides los cuales son muy importantes para el control del dolor de origen oncológico así como identificaron los factores de riesgo para 
el aparecimiento de la enfermedad. Además de eso, los pacientes que fueron bien asistidos por profesionales sanitarios presentaron más 
adhesión para el tratamiento del EIO. Conclusión: El control del EIO promueve el conforto del abdomen, el autocuidado y la reducción de 
los costes de tratamiento resaltando la necesidad de capacitación de los profesionales sanitarios, la prevención y el seguimiento periódico, 
además de la precocidad de los tratamientos de dieta y de medicamentos. 
Descriptores: Analgésicos Opioides; Estreñimiento; Dolor; Neoplasias. 
INTRODUCTION
Opioids are understood as any natural, semisynthetic or synthetic compound with properties similar to those of the 
endogenous opioids and that specifically bind to opioid receptors (mu, kappa, delta and epsilon), which are important in the 
normal regulation of pain sensation(1).
Opium is an original substance in the pharmacological group of opiates, extracted from the poppy (Papaver somniferum). 
Historically, it has been reported that the use of opioids goes back more than 4,000 years(2). In many historical events, the use of 
opium is mentioned, as in the opium war, in China, where its use was spread through smoking, and in the American civil war, 
with the massive use of opium orally, and morphine, subcutaneously, in soldiers wounded in combat, or as a way of supporting 
the conditions of battle(3).
Currently, opioids are used in situations of pain control in patients with neuropathic or mixed pain, low back pain, 
headache, neuralgia, arthritis, insomnia, inappetence, pre- and postoperative conditions, anesthesia, major burns, polytrauma(4)  
and oncology patients with or without therapeutic possibility(5).
Pain relief in cancer patients requires the use of this class of drugs to promote an improvement in the quality of life of 
these individuals. However, the administration of these drugs produces side effects(6), among which we can highlight the 
gastrointestinal tract infection, which can lead to constipation(7).
In a study of patients who received opioids for palliative pain treatment, it was observed that constipation occurred in more 
than half of the patients, being almost always persistent, even with the use of laxatives(8). Conversely, by means of a common 
observation, in an outpatient pain clinic of a reference hospital for cancer treatment in the North/Northeast regions, during 
interventions of doctors and multiprofessional residency students to opioid patients, an association was observed between 
adherence to treatments and bowel rehabilitation. Thus, this observation brought the need to understand the actual dimension 
of the opioid-constipation relationship. Therefore, the present study aimed to investigate the impact of Opioid-Induced 
Constipation (OIC) in the literature through the identification of the risk factors, symptoms and treatments.
METHODS
The proposed study is an integrative review of literature, which is a method for analyzing it broadly, promoting a solid 
theoretical foundation, which can contribute to discussions about methods and research results, and pointing out knowledge 
gaps that need to be fulfilled through new studies(9).
Thus, a survey of scientific publications was conducted between February and March 2016, in the electronic databases 
Virtual Health Library (VHL), Scientific Electronic Library Online (SciELO), Latin American and Caribbean Literature in 
Health Sciences (LILACS) and Medical Literature Analysis and Retrieval System Online (MEDLINE), using the descriptors “ 
analgesic opioid “, “constipation” and “pain”, in English, Portuguese and Spanish, correlated or isolated, in the period from 2011 
to 2016, which investigated patients in pain treatment with continuous use of opioid drugs and with constipation as a clinical 
outcome. The guiding question of the research was: how strong is the impact of drug interaction of opioids on constipation?
As exclusion criteria, studies on animal, without the use of opioids or without clinical outcome of constipation, as well as 
bibliographic reviews, theses, dissertations, monographs and texts that were duplicated in more than one database were rejected.
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Screening began after the identification of the articles that included the selected descriptors and met the inclusion criteria. 
Next, a selective reading of the articles was carried out, starting from the reading of the titles and abstracts, followed by the 
exploratory, analytical and interpretative analysis of the articles in full, with the purpose of making some considerations about 
the object of study of this research.
RESULTS
Initially, 48 articles were found, but only 10 included the eligibility criteria. The scientific articles were respectively 
organized and described in table I according to author/year, objective and main results.
Among the scientific articles selected, six were presented in English, two in Portuguese and two in the Spanish language. 
With regard to the objectives of the articles, 70% discuss issues related to the symptoms of constipation, but also address other 
issues, such as risk factors, drug and diet therapy, financial costs and the different perceptions of treatment.
Chart I - Articles description in accordance with author, year, objective, study population and results. 
Author/Year Objective Study population Results 
Dzierżanowski; 
Ciałkowska-
Rysz, 2015(10)
To evaluate the correlation 
between FqBM and risk 
factors for constipation in 
palliative care patients.
Patients in palliative care 
at three specialized centers 
submitted to questionnaires 
on the symptoms of intestinal 
dysfunction, behavioral risk 
factors and opioid use.
The main risk factors for 
constipation in palliative care 
patients were: insufficient fluid 
and food intake, inadequate 
privacy conditions, dependence 
on a caregiver, and overall poor 
performance as well.
Chumpitaz-
Corredor; Lara-
Solares, 2012(11) 
To report the effect 
of subcutaneous (SC) 
administration of MTNX (12 
mg) for relief from opioid-
induced constipation.
Terminal patients of the 
SZNIMSN, who were evaluated 
during admission by the pain 
and palliative care clinical team 
and presented constipation 
secondary to the treatment with 
opioids.
All patients had defecation after 
MTNX administration. There was 
no correlation between the opioid 
dose and the MTNX response time. 
There was no correlation between 
the dose of opioid and the days of 
constipation, nor between days 
of constipation and response to 
MTNX.
Gálvez et al., 
2014(12)  
To analyze the prevalence and 
severity of OIBD symptoms.
Outpatients diagnosed with 
cancer pain or chronic non-
oncologic pain treated with a 
single opioid.
Patients treated with opioid had a 
high frequency of bowel disorders. 
Constipation was the most common 
symptom, highlighting the need for 
new treatment strategies.
Takemoto et al, 
2011(13)  
To estimate the prevalence 
of constipation concomitant 
with opioid treatment and to 
compare the use of resources 
and costs in patients treated 
with opioids, with and 
without constipation, from 
the perspective of the private 
payer in Brazil.
Patients with constipation or 
undergoing related procedures 
during opioid treatment were 
identified by an algorithm 
in a longitudinal database of 
health insurance companies, 
divided into four groups: G1 
not treated with opioids without 
constipation; G2- not treated 
with opioids with constipation; 
G3- treated with opioids without 
constipation; G4- treated with 
opioids with constipation.
Patients with constipation who 
underwent opioid treatment 
imposed a greater economic burden 
than patients without this condition.
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Laugsand et al., 
2011(14)  
To examine the adequacy of 
treatment for constipation, 
nausea, depression and lack of 
sleep, and factors associated 
with inadequate symptom 
control in cancer patients 
undergoing opioid treatment.
Patients who received strong 
opioids for cancer pain, recruited 
from 17 centers in 11 European 
countries.
Most cancer patients had 
inadequate, ineffective, or absent 
treatment. There were subgroups 
of patients at particular risk 
(constipation, nausea, depression 
and poor sleep) for inadequate 
treatment, who may need special 
attention from HCPs for proper 
symptom control.
Tai et al., 
2016(15)  
To evaluate the severity of 
symptoms of advanced cancer 
patients in a palliative care 
unit and explore the factors 
associated with symptom 
improvement.
Patients of a palliative care unit 
in Taiwan.
The severity of symptoms decreased 
during the first week in the 
palliative care unit. Additionally, 
sex differences and primary cancer 
sites may contribute to different 
degrees of symptom improvement.
Nunes; Garcia; 
Sakata, 2014(16)  
To evaluate the use of morphine 
as the first drug for treatment 
of moderate oncologic pain in 
patients with advanced disease 
and/or metastasis, as an option 
to the recommendations of the 
analgesic ladder advocated by 
WHO.
Patients with cancer, aged ≥ 18 
years and without use of opioids. 
Division into two groups: G1- 
treated with drugs according 
to the analgesic ladder; G2 - 
treated with morphine.
The use of morphine as the first 
drug for treatment of pain did not 
promote better analgesic effect than 
the analgesic ladder recommended 
by the WHO and there was a higher 
incidence of adverse effects.
Marmo et al., 
2012(17)
To evaluate bowel habit 
of cancer patients using 
morphine.
Oncology patients monitored at 
the IPO pain outpatient clinic of 
the Federal University of São 
Paulo, SP.
Constipation was frequent, 
however, specific attention to bowel 
habits of these patients increased 
adherence to laxatives and reduced 
the formation of fecaloma.
Feudtner et al., 
2014(18)  
Compare patients who 
received Senna with similar 
patients who received other 
intestinal/oral medicine and 
determine the subsequent risk 
of “problematic constipation.”.
Cancer patients ≤ 20 years of 
age who,  during hospitalization, 
were exposed to seven or more 
days of consecutive opioid use 
and exposed to at least one 
intestinal/oral medicine during 
the first or second day of the 
reference period.
Initiating therapy with Senna, in 
comparison to other intestinal/
oral medicines, diminishes the 
subsequent risk of markers of 
problematic constipation in this 
population.
Locasale et al., 
2016(19)  
Describe the understanding of 
HCP by means of OIC patients’ 
report of experiences. To 
assess the degree of perception 
agreement or disagreement 
between the patients and their 
health professionals who treat 
OIC and the impact on clinical 
outcomes.
Patients aged 18-85 years who 
received daily treatment with 
opioids for ≥ 4 weeks to treat 
chronic non-oncologic pain in 
the presence of OIC.
The importance and severity of OIC 
are perceived differently by patients 
and their HCP, disagreement that 
complicates the management of 
pain and demonstrates the need for 
greater communication.
OIC = Opioid-induced constipation; OIBD = Opioid-induced bowel dysfunction; FqBM = Frequency of Bowel Movements; SZNIMSN = 
Salvador Zubirán National Institute of Medical Sciences and Nutrition; MTNX = Methylnaltrexone; IPO= Institute of Pediatric Oncology; 
WHO = World Health Organization; HCP = Health Care Providers.
DISCUSSION
The results found in this study pointed constipation as the main secondary effect to the use of opioids during pain treatment 
in all articles analyzed(10-19). In seven studies the reason for opioid use was directly related to the control of pain with exclusively 
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oncologic cause(10,11, 14-18), in two others the reason was mixed, oncologic/non-oncologic(12,13), and only one was exclusively non-
oncological(19). Additionally, the majority of the studied population had a mean age greater than or equal to 60 years(10,11,14,15), 
information that seems to suggest a positive correlation between cancer/old age for the use of opioids/OIC.
OIC is one of the causes of unresolved pain in patients during pain management. Normally, its responsiveness to regular 
laxatives is poor and this may be an obstacle to effective pain management(10). Furthermore, unlike other side effects, it does 
not develop tolerance over time, and increases with duration of treatment(10-12), being the most difficult problem during pain 
management with use of opioids(10).
One article pointed out that patients reported some degree of negative impact due to gastrointestinal effects after using 
opiods in aspects such as work, sleep quality, social relations, daily activities, quality of life and general mood, and also 
highlighted constipation as the more frequent cause for abandonment of long-term treatment(12).
From a financial cost perspective, it was observed in a study that OIC patients reported significantly more visits to the 
doctor and alternative care, besides being more likely to be in palliative care, which favors the increase in treatment costs, 
reinforcing the fact that, comparatively, OIC poses a greater influence on the use of resources and higher costs than patients 
without this condition(13).
To better understand the problem of this condition, the discussion of this research was divided into five thematic axes: 
symptoms and risk factors, cancer patients, drug therapy, diet therapy and impact of health professionals on treatment.
Symptoms and risk factors
Three articles define OIC as a symptom of opioid-induced bowel dysfunction (OIBD), which is a common complication 
of opioid treatment in chronic pain, characterized by reduced gastric emptying, stomach cramps, edema, reduced bowel 
movements and excessively hardened faeces(10-12). Among the symptoms, constipation is the most common and debilitating 
OIBD, with most prevalence estimates based only on the frequency of this primary symptom(12).
Six studies report that, in addition to constipation, other adverse effects, secondary to pain therapy, commonly occur and 
include: drowsiness, nausea, vomiting, acidity, flatulence, anorexia, distension and abdominal pain(10-12,14-16), which, sometimes, 
limit the benefit of the medicine and may lead to abandonment of treatment(12).
When administered for pain analgesia, opioid drugs have affinity for mu, delta and kappa receptors, which are responsible 
for the peripheral and central action of these drugs. However, they present selectivity problems, causing adverse effects to the 
expected, being mu receptor responsible for OIC(12). It has central action in the intestine and, when stimulated by the drug, 
influences the inhibition of intestinal peristalsis, decreasing motility(11).
Two papers suggest that OIC diagnosis should be based on objective and subjective symptoms. Objective symptoms, 
identified by less than three bowel movements per week, and subjective symptoms, identified by effort of difficult elimination, 
excessively hard stools, with reduced volume, sensation of incomplete evacuation, abdominal discomfort, gastric fullness and 
measures to facilitate the excretion of the fecal matter(10,12).
There are risk factors for the onset of OIC that make it difficult to diagnose(14). Four articles attributed these factors to 
debilitating aspects in patients’ functional capacity, such as: immobilization (especially in dorsal decubitus), low physical 
activity, advanced age, insufficient acceptance of fluids and food, abdominal cancer, lack of privacy, and clinical and emotional 
instability(10,11,14,17).  One study defined that the factors are subject to the presence of other gastrointestinal symptoms, and these, 
in turn, depended on the duration of pain, suggesting that the incidence of OIC probably occurs in patients in chronic pain 
treatment for 12 months or longer(12).  
When the reduction in functional capacity occurs, patients spend more time bedridden. Subsequently, appetite and thirst 
get reduced, so that, as the disease progresses, they become dependent on their caregivers. When the condition intensifies, they 
become more susceptible to uncomfortable situations for defecation. Thus, it is already possible to anticipate the diagnosis of 
constipation from the deterioration of a patient’s condition, which is important for creation of prophylactic actions. It is also 
worth noting that, regardless of the care regime, whether hospital or home, and the immobility, whether complete or partial, 
(wheelchair users or those who do not perform all movements), patients are affected to a similar degree by these risk factors(10). 
Defecation is a basic right to the dignity and honor of patients, an intimate act that must be respected. When privacy is not 
guaranteed, patients may be restrained in relation to bowel movements, leading to constipation by postponing defecation. This 
condition usually occurs among hospital patients, especially those in palliative care, since they are the most impaired, as the 
evacuation is liable to occur under the assistance of the healthcare team. In many cases, it is possible to reshape care and create 
a supportive environment in order to ensure the privacy of these patients(10).
Cancer patients
Considering that most of the population studied in the articles were elderly and have some type of cancer(10,11,14,15), it is 
possible to infer that age may present as a risk factor, for both constipation and cancer. The disease, when installed, can promote 
cancer pain and the search for pain control through the use of opioids, which, as a consequence, can cause constipation.
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Despite the recognition of old age as a risk factor for OIC, this does not mean that children and adolescents with cancer, 
treated with opioids, are immune to this condition; therefore, treatment recommendations should not be extrapolated to this 
population, which requires differential treatment to control the disease, since it presents its own physical, physiological and 
psychological characteristics(17).
Patients with cancer have a dynamic clinical situation, in relation to both the underlying disease and existing comorbidities, 
being subject to the same risk factors for OIC already mentioned, hindering the diagnosis of the possible causes of intestinal 
transit alteration and consequent effective treatment(17). However, symptom control is encouraged and should be treated as early 
as possible, because of the functional status deterioration when constipation is established(11), besides allowing the understanding 
of the problem and improvement of the clinical management(12).  
A study that separately analyzed cancer patients with and without constipation found that, comparatively, patients with 
cancer and constipation generated higher costs of treatment than patients with cancer and no constipation(13).
In advanced cancer, clinical conditions can become markedly deteriorated in the terminal phase, resulting in sudden 
worsening of symptoms, so the rapid and effective management of these symptoms is essential to ensure adequate comfort and 
a high “quality of death”(15).
Drug therapy 
Two studies stated that OIC adverse effects would be controlled with the prophylactic use of laxatives, and that laxative 
prescribing is recommended early in treatment(16,17).  Another study indicates that senna-based laxatives are well tolerated in 
children and adults on prolonged course of opioid therapy, provided that there are no contraindications, having little side effect 
and low financial cost compared to other pharmacological agents and techniques used to prevent or treat constipation, such as 
enemas or exposures to abdominal imaging(18).
Three studies consider it important that recommendations for the symptomatic treatment of ICD be followed and the initial 
dose be individualized, based on the intensity of the patient’s pain and the occurrence of adverse events, which may motivate 
the substitution of one opioid for another. This individualization suggests that the incidence of adverse, refractory or intolerable 
effects can be reduced and, in result, improve the patients’ quality of life (12,16,17).
With the same view, new opioid receptor-antagonist drugs with peripheral effects, such as oxycodone, naloxone and 
methylnaltrexone, despite having a mechanism of action similar to opioids, eventually present specific differences as for 
receptor affinity and pharmacodynamics, leading to positive differences in analgesia and reduction of side effects, and may be a 
substitute alternative to other opioids(11,12,17). In two studies, a lower tendency to use laxatives was attributed to such drugs(11,17).
In cases of established fecal impaction, the administration of enemas is indicated, regardless of causing pain, discomfort and 
being difficult to handle, as they promote temporary relief of symptoms and abdominal comfort. It consists in the elimination 
of impacted stool by means of rectal drug administration or by taking laxatives in high doses orally. However, this maneuver is 
contraindicated in certain clinical conditions, such as leucopenia, thrombocytopenia, anal lesion or severe immunosuppression, 
and without the prior consent of the patient(17).
Diet therapy
Just as drug therapy may be essential for the treatment of constipation, in a synergistic way, the incentive to change eating 
habits, with greater intake of fibers and liquids, can also be helpful in this condition, since they act directly on the functioning 
of the bowel and stool formation. Nevertheless, in order to achieve success in treatment, dietary guidelines should be explained 
as clearly as possible, so that patients and/or caregivers minimize possible errors and achieve treatment success(10).
It is a fact that, even under nutritional monitoring, with adequate supply of fluids and food, there are cases difficult or 
impossible to reverse due to the patient’s very condition, such as patients with cachexia, whose intake may be insufficient for 
normal functioning of intestinal transit and fecal consistency. In such cases, the use of fiber-based nutritional supplements is 
contraindicated and, as an effective strategy for prevention of constipation, it is recommended to increase the number of meals, 
with volume of liquids and foods adjusted to the individual tolerance(10).
The impact of health professionals on the treatment 
Despite the high incidence, the difficulties related to treatment, and the increase in the number of OIC studies, there is little 
improvement in health professionals’ understanding and communication in regard to the intensity of their patients’ symptoms, 
generating different perceptions of the importance and severity of the disease among the subjects(19). Four studies have pointed 
out that OIC and chronic pain are poorly valued or underestimated by health professionals, and that their symptoms receive 
poor attention, turning themselves to an inadequate treatment(11,14,17,19).
An article evidenced that the average prescription of opioids in Brazil is below the world average consumption, generating 
an indirect evidence of inadequate pain control in the country(13). When constipation and pain are underestimated, an obstacle to 
the management of these conditions is created14), which may favor the presence of negative behaviors on the part of the patient, 
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leading them to abandon or reduce the consumption of opioids with the intention of relieving the symptoms of constipation; or, 
conversely, the pain generated by the discomfort of the absence of bowel movements and abdominal distension may lead them 
to increase the drug consumption, creating a vicious cycle of intensification of pain and constipation, which could even lead 
to the creation of a state of acute confusion(11). On the part of health professionals, such a condition may contribute to a lack of 
awareness of the impact of the OIC(19).
Limited communication reagarding the symptoms may be related to both subjects. Lack of time and initiative is evidenced 
among health professionals, as they feel that patients should start the conversation, or by limiting their approach to aspects such 
as symptoms, laxatives, satisfaction, benefit and the impact of OIC on pain management. On the part of the patients, a lack of 
clarity regarding the level of symptoms or the omission of IOC symptoms are observed for several reasons, such as fear of not 
receiving the opioid, lack of understanding of the opioid-constipation relation, and the belief that constipation is a self-care 
condition, being often considered a constraint and kept non-shared(19).
In another study, it was observed that, when health professionals are attentive to the diagnosis, follow-up and treatment 
of constipation, it results in better adherence to the recommended laxatives, interfering positively in the management of the 
disease(17). Thus, aiming to reduce this problem, clinical education and coordination of care related to OIC management should 
be promoted among health professionals, in addition to an incentive to a more proactive posture during prevention, in which 
the communication about constipation is facilitated among the subjects since the onset of opioid treatment, making the patients 
commited to their own pain management, in order to avoid this condition(19).
CONCLUSION
Through this study it was possible to verify the impact of OIC in all its aspects: diagnosis of the symptoms, risk factors 
related to the onset of the condition, involvement in cancer pain treatment, as well as the modalities of existing treatments. 
Moreover, the disagreements between the patients’ and the health professionals’ perceptions of care were demonstrated, showing 
the existence of communication problems that can have negative repercussions in the treatment of the condition.
It is important that OIC be managed to provide abdominal comfort and self-care in patients, with a consequent reduction 
in treatment costs. To this end, it is necessary to train health professionals, prevention related to risk factor management, and 
periodic follow-up, in addition to the early onset of diet therapy (with dietary guidelines and encouragement to changes in 
eating habits) and drug therapy (with opioids prescribing adjusted according to changes in pain or adverse effects in the patient, 
and encouragement to the use of laxatives).
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